FY26 consensus $6.38B. BeOne’s total revenue guidance for full year 2026 of $6.3B-$6.5B includes expectations for strong revenue growth driven by BRUKINSA’s leadership position in the U.S. and continued global expansion in both Europe and other important rest of world markets. Gross margin percentage is expected to be in the high-80% range and includes the impact of product mix and a full year of 2026 productivity improvements. Guidance for combined operating expenses on a GAAP basis includes expectations of investment to support growth in both commercial and research at a pace that continues to deliver meaningful operating leverage.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- AMD downgraded, Airbnb upgraded: Wall Street’s top analyst calls
- BeOne Medicines initiated with an Overweight at Wells Fargo
- BeOne Medicines: FDA grants Priority Review to sBLA for tevimbra/ziihera combo
- BeOne Medicines price target lowered to $411 from $412 at Truist
- Buy Rating on BeOne Medicines: Strong Brukinsa Positioning, Deep Oncology Pipeline, and Attractive Valuation Ahead of 2026 Milestones